Study reveals over 134,000 missed cancer diagnoses in the U.S. during COVID-19 pandemic

A dose-reduction strategy for a commonly used first-line combination in pancreatic cancer resulted in similar survival outcomes but improved tolerability, a randomized phase II study

When Re­gen­eron an­nounced a $500 mil­lion cor­po­rate ven­ture cap­i­tal fund last week, it was the first time in years that a sto­ried large phar­ma had